{'fraction_non_alphanumeric': 0.029087261785356068, 'fraction_numerical': 0.003009027081243731, 'mean_word_length': 5.438709677419355, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Comparison of Tyloxapol (Tacholiquin, Alevaire) with physiological saline as inhalation carrier solutions].

By means of a double-blind crossover study the effects of tyloxapol (Tacholiquin, Alevaire) and saline as carrier solutions for the inhalation of beta-agonists have been compared in 24 paitents with bronchial asthma. Specific airway conductance was measured repeatedly over a 2-hour period in order to assess changes of airway caliber due to the inhalation. The results reveal a significant bronchoconstrictive effect of tyloxapol as compared with saline. The bronchodilator activity of solutions with tyloxapol and beta-agonists (orciprenaline, salbutamol) was no better than those with saline and the same beta-agonists. However, side effects (symptoms of airway irritation, increase of pulse rate) were more pronounced with tyloxapol. In view of the direct effects of inhalation with a beta-agonist, no advantage of the expensive carrier solution tyloxapol over saline could be shown.